Funding

HIV-VAC Announces $5 Million Funding Commitment to Develop AIDS Vaccine

Published in Vaccine Weekly, September 6th, 1999

HIV-VAC, Inc., Toronto, Ontario, Canada, has announced that the company has received a funding commitment totaling $5 million from an Australian investment group to complete initial test trials of HIV-VAC's AIDS vaccine with the Russian Aids Centre, and later proceed to the Phase III trials and product licensing.

Dr. Gordon Skinner, MD (Hons), DSc, FRCOG, FRCPath, is the developer of HIV-VAC's AIDS vaccine. The vaccine has been under development by Dr. Skinner and his team for the past 10 years at the University of Birmingham, United Kingdom. Pre-clinical testing is nearing completion.

Like VaxGen and Vical, HIV-VAC is working with alternative...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (1999-09-06)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry